Chris Garabedian – Orphan Drug Congress Interview Part 1

In Uncategorized by Karina Kusova

Andre Singer (Project Director- World Orphan Drug Congress USA) and Chris Garabedian(Former CEO of Sarepta Therapeutics) discuss the current state of affairs in the Orphan Drug Space for the upcoming World Orphan Drug Congress 2017, taking place in Washington D.C on April 19-21st. Topics include accelerated approval, rare disease commercialization business models, regulatory updates and others.

At the World Orphan Drug Congress USA in April 2017, we are bringing together more than 170 elite speakers to educate and inspire our 1,000 attendees from big pharma, biotech, payers, patient groups, academics and government bodies. In 2017, World Orphan Drug Congress USA is bringing together the worlds of Scientific Innovation and Commercialization, with 2 tracks in the main conference.

By exploring trends in Digital Health, Biosimilars, Gene Therapy, and more, we will uncover the next scientific breakthroughs in rare disease. Examinations of Mergers, Commercialization, Marketing and the Regional Markets will provide insight into this billion-dollar business. That’s not all, with Rare Disease Advocacy World and Pitch and Partner 2017, there are 4 tracks of content for you and your team to enjoy.

Register now >>